Clinical Report: YUVEZZI Campaign Targets Presbyopia

Overview

Tenpoint Therapeutics has launched a national campaign for YUVEZZI, a prescription eye drop approved for presbyopia.

Background

Presbyopia is a common age-related condition that typically begins around age 45, affecting approximately 128 million adults in the US and about 2 billion people globally. It can interfere with daily activities such as reading and using digital devices. YUVEZZI is a dual-agent ophthalmic solution approved for managing this condition.

Data Highlights

YUVEZZI (carbachol and brimonidine tartrate) is approved for adults with presbyopia and has shown efficacy in clinical studies, providing up to eight continuous hours of improved close-up vision.

Key Findings

• YUVEZZI is the first dual-agent eye drop approved for presbyopia treatment.
• Clinical studies demonstrated responder rates of 19.4% to 38.2% at various time points compared to vehicle controls.
• Common side effects include headache, impaired vision, and temporary eye pain.

Clinical Implications

Healthcare professionals should be aware of YUVEZZI as a treatment option for presbyopia and consider discussing its benefits and potential side effects with patients.

Conclusion

The launch of the YUVEZZI campaign is intended to raise awareness about presbyopia.

Related Resources & Content

1. Contact Lens Spectrum, 2026 -- Tenpoint Therapeutics Launches Yuvezzi Direct-to-Consumer Campaign
2. The Ophthalmologist, 2026 -- Dual-Agent Eye Drop for Presbyopia
3. Ophthalmology Management, 2026 -- FDA Approves Yuvezzi Combination Eye Drop for Presbyopia
4. The Ophthalmologist, 2026 -- Dual-Mechanism Drop Wins FDA Approval
5. FDA Label, 2026 -- Yuvezzi
6. Presbyopia - EyeWiki
7. label
8. https://qlosi.com/hubfs/Prescribing%20Information%2005-2025.pdf?hsLang=en